| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
3 companies
Commodore Capital LP last filed a Form 4 in January 2024, as 10% Owner at VERA. The filings on record cover 3 companies.
Our model assigns Commodore Capital LP a below-average insider score of 33/100, based on 6 past trades. Over a 12-month horizon, 16.7% of those trades were profitable, with an average 12-month return of -25.7%.
At the last filing, the largest reported position was 4,400,000 shares of VERA. The VERA filings lean toward selling, a net 601,783 shares.
Commodore Capital LP has 6 Form 4 filings on record from February 2023 to January 2024, across 3 companies: 10% Owner at Vera Therapeutics (VERA), 2023–2024; 10% Owner at Vistagen Therapeutics (VTGN), 2023; 10% Owner at Enliven Therapeutics (ELVN), 2023.
The 10 reported transactions were 5 open-market purchases, 3 option or other derivative awards, 1 open-market sale and 1 other transaction.
Counted by filing, the open-market trades come to 4 purchases worth about $24.9M and 1 sale worth about $18.9M.
The largest open-market purchase was 775,756 shares of VTGN at an average $23.15 on August 7, 2023, about $18.0M. Twelve months later VTGN was down 75%.
The only open-market sale was 1,050,000 shares of VERA at an average $18.00 on January 10, 2024, about $18.9M. Twelve months later VERA was up 93%.
Shares as reported in the last Form 4 for each company; the most recent is from January 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 10, 2024 | VERA Vera Therapeutics, Inc. | 10% Owner | Sell | 1,050,000 | $18.00 | $18,900,000.00 | -19.3% | +97.6% | +92.9% | |
| Aug 7, 2023 | VTGN Vistagen Therapeutics, Inc. | 10% Owner | Buy | 775,756 | $23.15 | $17,961,078.67 | +97.1% | -74.0% | -75.5% | |
| Jun 20, 2023 | VERA Vera Therapeutics, Inc. | 10% Owner | Buy | 448,217 | $15.17 | $6,799,003.67 | +9.0% | +10.9% | +136.9% | |
| Feb 23, 2023 | ELVN Enliven Therapeutics, Inc. | 10% Owner | Buy | 622 | $22.07 | $13,723.27 | - | -22.0% | -34.6% | |
| Feb 22, 2023 | ELVN Enliven Therapeutics, Inc. | 10% Owner | Buy | 31,759 | $5.15 | $163,498.15 | +1.1% | -10.0% | -27.1% |